Modulation of N-Methyl-d-aspartate Receptors by Donepezil in Rat Cortical Neurons

Nicotinic acetylcholine receptors and N -methyl- d -aspartate (NMDA) receptors are known to be down-regulated in the brain of patients with Alzheimer's disease. It was previously shown that the nootropic drugs nefiracetam and galantamine potentiate the activity of both nicotinic and NMDA recept...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2005-10, Vol.315 (1), p.125-135
Main Authors: Moriguchi, Shigeki, Zhao, Xilong, Marszalec, William, Yeh, Jay Z, Narahashi, Toshio
Format: Article
Language:English
Subjects:
Acetylcholine - pharmacology
Animals
Cerebral Cortex - drug effects
Cyclic AMP-Dependent Protein Kinases - physiology
Dose-Response Relationship, Drug
Female
GTP-Binding Proteins - physiology
Indans - pharmacology
Neurons - drug effects
Nootropic Agents - pharmacology
Piperidines - pharmacology
Pregnancy
Protein Kinase C - physiology
Rats
Rats, Sprague-Dawley
Receptors, N-Methyl-D-Aspartate - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nicotinic acetylcholine receptors and N -methyl- d -aspartate (NMDA) receptors are known to be down-regulated in the brain of patients with Alzheimer's disease. It was previously shown that the nootropic drugs nefiracetam and galantamine potentiate the activity of both nicotinic and NMDA receptors. We hypothesized that donepezil, a nootropic with a potent anticholinesterase activity, might also affect the NMDA system. NMDA-induced currents were recorded from rat cortical neurons in primary culture using the whole-cell patch-clamp technique at a holding potential of –70 mV in Mg 2+ -free solutions. In multipolar neurons, NMDA currents were decreased by bath and U-tube applications of 1 to 10 μM donepezil but were increased by 30 to 100 μM donepezil. Donepezil suppression occurred in a manner independent of NMDA concentrations ranging from 3 to 1000 μM. The donepezil suppression of NMDA currents was prevented by inhibition of protein kinase C (PKC) but unaffected by protein kinase A (PKA) and G proteins. In bipolar neurons, however, NMDA currents were potently augmented by bath and U-tube applications of 0.01 to 100 μM donepezil. Donepezil potentiation occurred at high NMDA concentrations that evoked the saturating responses and in a manner independent of NMDA concentrations ranging from 3 to 1000 μM. The potentiation of NMDA currents by donepezil was decreased by inhibition of PKC and abolished by modulation of G proteins but not by PKA inhibition. It was concluded that donepezil at low therapeutic concentrations (0.01–1 μM) potentiated the activity of the NMDA system and that this action together with cholinesterase inhibition would contribute to the improvement of learning, memory, and cognition in patients with Alzheimer's disease.
ISSN:0022-3565
1521-0103
DOI:10.1124/jpet.105.087908